|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
04-01-2010, 04:05 AM
|
|||
|
|||
pSivida Reports Presentation of Additional Positive 24-Month Data from Iluvien Phase
WATERTOWN, Mass.----pSivida Corp. , a leader in the development of ophthalmic sustained release drug delivery products, with two of the only three such products approved by the FDA for treatment of back of the eye diseases, today said that 24-month data from the FAME Phase 3 study for Iluvien presented at Angiogenesis 2010 included additional efficacy and safety data that reinforced the positive ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive m | cancerfr | Vaginal Cancer | 0 | 06-07-2010 07:43 PM |
| NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas canc | cancerfr | Pancreatic Cancer | 0 | 06-07-2010 07:43 PM |
| Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH | cancerfr | Penile Cancer | 0 | 06-02-2010 04:30 PM |
| Provectus Reports Further Positive Phase 2 Data On PV-10 For Metastatic Melanoma At A | cancerfr | Melanoma | 0 | 05-26-2010 05:14 PM |
| ZymoGenetics Announces Upcoming Presentation Of Positive IL-21 Phase 2 Results In Met | cancerfr | Melanoma | 0 | 05-23-2010 02:52 AM |
Linear Mode
